Goldman Sachs
ORKA

Goldman Sachs’s Oruka Therapeutics ORKA Stock Holding History

Goldman Sachs’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.1M Buy
246,711
+153,716
+165% +$5.34M ﹤0.01% 2890
2025
Q4 		$2.82M Buy
92,995
+73,220
+370% +$2.04M ﹤0.01% 4274
2025
Q3 		$380K Sell
19,775
-52,474
-73% -$778K ﹤0.01% 5649
2025
Q2 		$810K Sell
72,249
-171,950
-70% -$1.79M ﹤0.01% 4845
2025
Q1 		$2.51M Buy
+244,199
New +$3.05M ﹤0.01% 3963
2021
Q3 		– Sell
-1,160
Closed -$49K – 6565
2021
Q2 		$49K Buy
+1,160
New +$48.4K ﹤0.01% 6069
2021
Q1 		– Sell
-2,525
Closed -$121K – 6402
2020
Q4 		$121K Buy
+2,525
New +$126K ﹤0.01% 5259
2017
Q3 		– Sell
-75
Closed -$39K – 6897
2017
Q2 		$39K Sell
75
-2
-3% -$1.04K ﹤0.01% 6419
2017
Q1 		$43K Sell
77
-17
-18% -$9.49K ﹤0.01% 6336
2016
Q4 		$58K Sell
94
-8
-8% -$4.26K ﹤0.01% 6348
2016
Q3 		$62K Buy
102
+51
+100% +$32.9K ﹤0.01% 6403
2016
Q2 		$32K Buy
+51
New +$37.7K ﹤0.01% 6574
2014
Q4 		– Sell
-8
Closed -$15K – 7344
2014
Q3 		$15K Sell
8
-2
-20% -$4.18K ﹤0.01% 7019
2014
Q2 		$22K Buy
+10
New +$23.3K ﹤0.01% 6865

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs's ORKA Position: Q1 2026 in Review

Goldman Sachs increased its Oruka Therapeutics (ORKA) stake by 165% in Q1 2026, buying an estimated $5.34M and bringing the position to 246,711 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2890.

Goldman Sachs first reported a position in ORKA in Q2 2014 and has held it in 14 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Goldman Sachs held 246,711 shares of Oruka Therapeutics worth $12.1M as of Q1 2026.
  • Goldman Sachs bought 153,716 Oruka Therapeutics shares in Q1 2026, an estimated $5.34M.
  • Oruka Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2890 holding.
  • Goldman Sachs first reported a position in Oruka Therapeutics in Q2 2014 and has held it in 14 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.